Innate Pharma Total Revenue

The latest total revenue for IPHA is $12M as of December 2025. That compares with $69M in the prior-year period — down 82.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Innate Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPHA's total revenue moved from $69M to $12M — a 82.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Innate Pharma's operating scale or balance-sheet position.

Against Healthcare companies, IPHA currently prints $12M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Innate Pharma's growth, margins, and balance sheet.

A total revenue figure of $12M for IPHA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting IPHA's total revenue ($12M), review year-over-year change from $69M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.